Grail Stock Surges After TD Cowen Upgrade to Buy

Grail Stock Rises on TD Cowen Upgrade

Grail Inc. (NASDAQ:GRAL) shares increased by 6.2% on Wednesday following an upgrade from TD Cowen. The firm elevated the stock to a Buy rating from Hold and established a new price target of $65.00.

Market Context and Trial Results

The upgrade is notable as it follows a recent setback where Grail's pivotal NHS Galleri trial missed its primary endpoint, leading to a 60% decline in its share price. Despite this, TD Cowen remains constructive on the Multi-Cancer Early Detection (MCED) market, which it estimates has a total addressable market of $70 billion.

Analyst Outlook and Economic Impact

TD Cowen analyst Dan Brennan noted that feedback from key opinion leaders presents a more optimistic outlook than the trial data suggests. This feedback supports a path toward FDA approval and indicates an approximately 50% probability of Medicare approval. The $65 price target represents a 37% potential upside from the stock's previous closing price.

Summary

While the recent trial results posed a significant challenge, the analyst upgrade highlights a belief in the long-term viability and market potential of Grail's cancer detection technology. Investors will be closely watching for regulatory developments with the FDA and Medicare.

FAQ

Q: Why did Grail's stock increase?
A: The stock rose after TD Cowen upgraded its rating to Buy from Hold, citing optimism in the multi-cancer early detection market despite a recent trial setback.

Q: What is TD Cowen's new price target for Grail (GRAL)?
A: TD Cowen set a new price target of $65.00 for Grail stock, representing a significant potential upside.

Source: Investing.com